Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-20
2008-05-20
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S402000, C548S311400, C548S354100
Reexamination Certificate
active
07375125
ABSTRACT:
Provided are MC4-R binding compounds of the formula XVII:wherein L2is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
REFERENCES:
patent: 4598077 (1986-07-01), Fujii et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 2003/0096827 (2003-05-01), Yu et al.
patent: 1418053 (1975-12-01), None
patent: 05156475 (1993-06-01), None
patent: WO-97/47316 (1997-12-01), None
patent: WO-99/64002 (1999-12-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 02/062766 (2002-08-01), None
Vergoni et al., PubMed Abstract (Eur J Pharmacol. 405(1-3):25-32) Sep. 2000.
Ramos et al., PubMed Abstract (Curr Opin Clin Nutr Metab Care. 7(4):427-34) Jul. 2004.
Lechan et al., Editorial: Hypothalamic Melanocortin Signalling in Cachexia, Endocrinology, 142(8):3288-3291, Aug. 2001.
Hagan et al., Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade, Am J Physiol Integrative Comp Physiol. 279: R47-R52, 2000.
Yamaguchi, CAPLUS Abstract 120:220508, 1994.
Scholz et al., “Inhibition of FceRl-Mediated Activation of Mast Cells by 2,3,4-Tryhydropyrimidino[ 2,1-a]isoquinolines,”Journal of Medicinal Chemistry. 47(7), pp. 1050-1059, Mar. 1998.
Legrand, Chemical Abstract 87:5904, 1977.
Bednarek, Maria A. et al. “Analogs of MTII, Lactam Derivatives of .alpha.-Melanotrophin Modified at the N-terminu, and Their Selectively at Human Melanocortin Receptors 3, 4, and 5.”Biochemical and Biophysical Research Communications. vol. 261, pp. 209-213 (1999).
Kask, Ants et al., “Selective Antagonist for the MelanoCortin 4 Receptor (HS014) Increase Food Intake in Free-Feeding Rats.”Biochemical and Biophysical Research Communications. vol. 245, pp. 90-93 (1998).
Haskell-Luevano, Carrie et al., “Biological and Conformational Examination of Stereochemical Modifications Using the Template Melanotropin Peptide, Ac-Nle-c-[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on Human Melanocortin Receptors.”Journal of Medicinal Chemistry. vol. 40, pp. 1738-1748 (1997).
Vos, T.J. et al., “Identification of 2-'2-'2-(5-Bromo-2-methoxyphenyl)-ethyl-3-fluoro-phenyl-4,5-dihydro-1H-imidazole (ML00253764), a Small Molecule Melanocortin Receptor Antagonist That Effectively Reduces Tumor Induced Weight Loss in a Mouse Model.”Journal of Medicinal Chemistry. vol. 47(7), pp. 1602-1604 (2004).
Claiborne Christopher F.
Dai Mingshi
Maguire Martin P.
Marsilje Thomas H.
Patane Michael
Haddaway Keith G.
Ore Pharmaceuticals Inc.
Rao Deepak
Venable LLP
LandOfFree
Melanocortin-4 receptor binding compounds and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanocortin-4 receptor binding compounds and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanocortin-4 receptor binding compounds and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2805279